Genetic testing in the management of inherited arrhythmia syndromes.
Although the first gene responsible for long QT syndrome was described more than a decade ago, only now has the genetic testing become readily available to clinicians treating patients with inherited arrhythmia syndromes. Recognition of these syndromes, including long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and arrhythmogenic right ventricular cardiomyopathy, is important for both internists and cardiologists. The potential for malignant ventricular arrhythmias and sudden cardiac death makes integration of clinical and genetic information critical for managing these patients. Although the presence of variable penetrance and genotype-phenotype correlations can limit the effectiveness of widespread genetic screening, directed genetic testing can be very helpful in confirming diagnosis, delineating prognosis, and identifying high-risk individuals.
Tzou
Wendy S
WS
Department of Medicine, Cardiovascular Medicine Division, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
Gerstenfeld
Edward P
EP
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D053840:Brugada Syndrome; D030342:Genetic Diseases, Inborn; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D006352:Heart Ventricles; D006801:Humans; D010597:Pharmacogenetics; D018570:Risk Assessment; D012307:Risk Factors
D000889:Anti-Arrhythmia Agents